Opportunity Radar

← Back to search

Grant

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
G
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
RFA-TR-25-002
Posted
Dec 6, 2024
Response due
Jul 2, 2027
Archive date
Aug 1, 2027
CFDA / Assistance listing
93.350
Contact
grantsinfo@nih.gov
Source
Grants.gov

Description

This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

Similar open opportunities